Once-yearly jab for HIV protection passes first trial hurdle
Once-yearly jab for HIV protection passes first trial hurdle Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.hivvaccineLINK
Once-yearly jab for HIV protection passes first trial hurdle Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.hivvaccineLINK